Opinion|Videos|August 12, 2024
Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing
Key opinion leaders examine recent evidence on acquired BTK inhibitor resistance in chronic lymphocytic leukemia and analyze its implications for treatment sequencing decisions in clinical practice.
Advertisement
Episodes in this series
- Briefly discuss the latest evidence surrounding acquired BTKi resistance in CLL. What clinical insights do recent data provide?
- DrDAVIDS:ELEVATE-RR –
Woyach J et al. ICML 2023. Abstract 163 ;Poster 163 - (57:40 – follow up Q) invitro datanot hte end all be all.
- DrDAVIDS:ELEVATE-RR –
Dr Coombs to Group:What implications may these findings have on treatment sequencing? Is there a potential role of testing for acquired mutations upon disease progression?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
The OncFive: Top Oncology Articles for the Week of 8/30
5